In Azurity Pharms., Inc. v. Alkem Labs. Ltd., 2023 U.S. Dist. LEXIS 22848 (D. Del. Feb. 10, 2023), the district court held that Alkem’s ANDA infringes Azurity’s asserted claims, but the claims are invalid due to lack of written description support and obviousness.
